GUT: 质子泵抑制剂的使用可能会增加胃癌的发生率

2021-05-22 MedSci原创 MedSci原创

胃癌是全世界第六大最常见的癌症,癌症相关死亡率则排第三位,慢性幽门螺杆菌感染是胃癌的最强危险因素。根除幽门螺杆菌可减少胃癌的发生。

      胃癌是全世界第六大最常见的癌症,癌症相关死亡率则排第三位,慢性幽门螺杆菌感染是胃癌的最强危险因素。根除幽门螺杆菌可减少胃癌的发生。但是,根除幽门螺杆菌并没有完全预防胃癌的发生。质子泵抑制剂(PPI)是作用于胃H+/K+ATPase的抑制剂并已被用于消化性疾病的治疗。长期使用PPI可能会增加患胃病的风险,即使在根除幽门螺杆菌后仍会罹患癌症。因此,本项研究旨在评估PPI使用与胃癌之间的关系。

 

      研究人员分析了2002年至2013年间韩国国家健康保险服务数据库的原始数据,对所有接受一年PPI治疗的患者均进行了回顾性研究,通过Cox比例风险模型比较了PPI与其他药物之间胃癌的发生率,最后还分析了幽门螺杆菌根除后PPI使用者中胃癌的发生率。

 

     本项研究共纳入了11741例接受PPI治疗和非PPI治疗的患者。在4.3年的中位随访期间,使用PPI与胃癌发生率增加2.37倍相关(HR 2.37,95%CI 1.56-3.68,p = 0.001)。胃癌的发病也与PPI的使用时间有关。在幽门螺杆菌根除的受试者中,与非PPI组相比,胃癌的发生率与180天以上的PPI使用显着相关( HR 2.22,95%CI 1.05至4.67,p = 0.036)。

图:PPI对于胃癌的影响

      本项研究证实PPI的使用与胃癌的发生率有关,而与幽门螺杆菌的根除状态无关。在胃癌高风险地区应谨慎长期使用PPI。

 

 

原始出处:

Seung In Seo. Et al. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. GUT.2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1852667, encodeId=b7d6185266eed, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Sep 05 05:15:47 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066747, encodeId=34851066e473f, content=学习的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/7274ed1be4747d648e4e2f7f62fae403.jpg, createdBy=d8d65273314, createdName=1482963am12暂无昵称, createdTime=Thu Nov 04 00:13:25 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826692, encodeId=fceb182669203, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Oct 22 02:15:47 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667392, encodeId=b9c9166e392eb, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Mar 28 05:15:47 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
    2021-09-05 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1852667, encodeId=b7d6185266eed, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Sep 05 05:15:47 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066747, encodeId=34851066e473f, content=学习的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/7274ed1be4747d648e4e2f7f62fae403.jpg, createdBy=d8d65273314, createdName=1482963am12暂无昵称, createdTime=Thu Nov 04 00:13:25 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826692, encodeId=fceb182669203, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Oct 22 02:15:47 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667392, encodeId=b9c9166e392eb, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Mar 28 05:15:47 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
    2021-11-04 1482963am12暂无昵称

    学习的

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1852667, encodeId=b7d6185266eed, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Sep 05 05:15:47 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066747, encodeId=34851066e473f, content=学习的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/7274ed1be4747d648e4e2f7f62fae403.jpg, createdBy=d8d65273314, createdName=1482963am12暂无昵称, createdTime=Thu Nov 04 00:13:25 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826692, encodeId=fceb182669203, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Oct 22 02:15:47 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667392, encodeId=b9c9166e392eb, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Mar 28 05:15:47 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1852667, encodeId=b7d6185266eed, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Sep 05 05:15:47 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066747, encodeId=34851066e473f, content=学习的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/15/7274ed1be4747d648e4e2f7f62fae403.jpg, createdBy=d8d65273314, createdName=1482963am12暂无昵称, createdTime=Thu Nov 04 00:13:25 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826692, encodeId=fceb182669203, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Oct 22 02:15:47 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667392, encodeId=b9c9166e392eb, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Mon Mar 28 05:15:47 CST 2022, time=2022-03-28, status=1, ipAttribution=)]

相关资讯

Br J Cancer:胃癌肝转移的潜在治疗靶标GNG4

胃癌作为一种源于胃黏膜上皮的恶性肿瘤,是第三大癌症死亡原因。

GUT:中高危胃肠化生患者要定期内镜检查评估肠化生情况,预防胃癌

胃癌(GC)是世界上第五大常见癌症和第三大癌症相关死亡原因,死亡率高的主要原因是发病较晚。超过70%的国家报告了胃癌的高死亡率/发病率(>0.8)。只有日本和韩国的死亡率/发病率较低(分别为0.

胃癌有无转移?影像检查+人工智能可准确预测,避免“白挨一刀”

5月14——15日,2021年中国研究型医院学会数字智能化外科专业委员会学术年会暨第二届国际数字智能化诊疗技术大会在广州召开。中国科学院院士刘允怡、陈孝平及来自国内外的80余位

Gut:可预测胃癌从紫杉醇治疗中获益的基因特征

一个可预测胃癌患者从紫杉醇治疗中获益的首个生物标志物

Gut:胃肠化生的严重程度预测胃癌的发生:一项前瞻性队列研究(GCEP)

胃肠化生(IM)是促进早期胃癌发生的危险因素,建议采用风险分层方法,并建议高危患者(OLGIM III-IV)在2年内接受内镜监测,中危患者(OLGIM II)在5年内接受内镜监测。

Gut:机器学习模式鉴别胃癌紫杉醇生存获益的基因集:来自III期随机临床试验SAMIT的数据分析

胃癌是常见的恶性肿瘤。术前或术后的化疗都能给患者带来生存获益。目前常用的药物有5-FU,铂类以及紫杉醇类药物。有研究报道了预测5-FU以及铂类药物生存获益的标志物。但是对于紫杉醇获益的生物指标仍没有报